Body Mass Index and Disease Activity in Chronic Inflammatory Rheumatic Diseases: Results of the Cardiovascular in Rheumatology (Carma) Project

Jesús A. Valero-Jaimes 1,†, Ruth López-González 2,‡, María A. Martín-Martín 3, Carmen García-Gómez 4, Fernando Sánchez-Alonso 5, Jesús T. Sánchez-Costa 5, Carlos González-Juanatey 5, Eva Revuelta-Evrad 6, César Díaz-Torné 7, Cruz Fernández-Espartero 8, Carolina Pérez-García 9, Vicenç Torrente-Segarra 10, Ginés Sánchez-Nievas 11, Trinidad Pérez-Sandoval 12, Pilar Font-Ugalde 13, María L. García-Vivar 14, Elena Aurrecoechea 15, Olga Maiz-Alonso 1, Ramón Vallés-García 16, José A. Miranda-Filloy 17, Javier Llorca 18, Santos Castañeda 19,‡ and Miguel A. González-Gay 20,21,22,*,† on behalf of the CARMA Study Group

Abstract: Objective: Since obesity has been associated with a higher inflammatory burden and worse response to therapy in patients with chronic inflammatory rheumatic diseases (CIRD), we aimed to...
confirm the potential association between body mass index (BMI) and disease activity in a large series of patients with CIRDs included in the Spanish CARdiovascular in rheuMATology (CARMA) registry. Methods: Baseline data analysis of patients included from the CARMA project, a 10-year prospective study of patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA) attending outpatient rheumatology clinics from 67 Spanish hospitals. Obesity was defined when BMI (kg/m²) was >30 according to the WHO criteria. Scores used to evaluate disease activity were Disease Activity Score of 28 joints (DAS28) in RA, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in AS, and modified DAS for PsA. Results: Data from 2234 patients (775 RA, 738 AS, and 721 PsA) were assessed. The mean ± SD BMI at the baseline visit were: 26.9 ± 4.8 in RA, 27.4 ± 4.4 in AS, and 28.2 ± 4.7 in PsA. A positive association between BMI and disease activity in patients with RA (β = 0.029; 95%CI (0.01- 0.05); p = 0.007) and PsA (β = 0.036; 95%CI (0.015–0.058); p = 0.001) but not in those with AS (β = 0.001; 95%CI (−0.03–0.03); p = 0.926) was found. Disease activity was associated with female sex and rheumatoid factor in RA and with Psoriasis Area Severity Index and enthesitis in PsA. Conclusions: BMI is associated with disease activity in RA and PsA, but not in AS. Given that obesity is a potentially modifiable factor, adequate control of body weight can improve the outcome of patients with CIRD and, therefore, weight control should be included in the management strategy of these patients.

Keywords: body mass index; obesity; rheumatoid arthritis; ankylosing spondylitis; psoriatic arthritis and disease activity

1. Introduction

Obesity constitutes a major epidemic, in particular in developed countries. It affects around 35% of the general population according to the World Health Organization (WHO) [1]. In Spain, it reaches 21.6% of the global population, according to data from the Nutritional Study of the Spanish Population (ENPE-2015) [2]. Some studies suggest that there is a higher prevalence of obesity in individuals with rheumatoid arthritis (RA), psoriatic arthritis (PsA) [3–5], and ankylosing spondylitis (AS) [6].

A number of studies have confirmed that adipose tissue is a metabolically active organ, representing an important source of inflammatory mediators, known as adipokines or adipocytokines. They promote a pro-inflammatory state in obese subjects, establishing obesity as a low-grade inflammatory disease [7,8].

Higher body mass index (BMI) values are negatively associated with anti-TNF drug levels in plasma and, as a consequence, obesity has been associated with higher disease activity rates and worse response to therapies [9–12]. The relationship between obesity and disease activity has been reflected in some studies in patients with RA and PsA. Regarding AS, this relationship is less clear. However, some studies suggest a possible link between disease activity in patients with AS and excess fatty tissue [13,14]. In this regard, higher BMI values have been associated with lower response rates mainly to infliximab (IFX) [15] and other anti-TNF agents in patients with spondyloarthritis [16,17].

Taking all these considerations into account, the purpose of the present study was to confirm the potential association between BMI and disease activity in a large series of patients with chronic inflammatory rheumatic diseases (CIRD) included in the Spanish CARdiovascular in rheuMATology (CARMA) registry.

2. Patients and Methods

2.1. Study Design

The CARdiovascular in rheuMATology (CARMA) project is a prospective 10-year follow-up cohort study designed to determine the risk of cardiovascular mortality in patients with CIRDs compared to a cohort of patients without CIRD [18]. For the present study, a cross-sectional analysis of the initial visit has been performed to determine the relationship between disease activity and BMI at the baseline visit (time of recruitment).
2.2. Patient Recruitment

All Spanish public hospitals (university and general hospitals) with Rheumatology Units included in the Spanish Rheumatology Society (Sociedad Española de Reumatología-SER) database, which includes more than 90% of the country’s hospitals, were invited to participate in the registry. Finally, 67 institutions (63.2% of all centers contacted) were included in the project. Overall, the patients recruited for the study were 2234. They attended rheumatology outpatient clinics at tertiary or secondary care centers between July 2010 and January 2012. Patients were included in the registry if they were older than 18 years and met at least 4 criteria of the American College of Rheumatology (ACR) 1987 for RA [19], the modified New York criteria for definite AS [20] or, in the case of PsA, the Moll and Wright criteria [21].

Information regarding the sample size and the baseline characteristics of the recruited participants, patients, and controls has previously been described by Castañeda et al. [18]. The study protocol was performed according to the principles of the Helsinki Declaration and it was approved by the Ethics Committee for Clinical Research of Lugo, Galicia (Spain), and subsequently also in each participant center (protocol number: 2009/077).

2.3. Variables and Operative Definitions

All included patients were evaluated on a continuous and systematic basis. To verify the quality of the information, an on-site evaluation of the follow-up data was performed randomly in 15% of the selected patients. The primary variable studied was the disease activity, which was measured through the Disease Activity Score of 28 joints (DAS28) [22] in the baseline visit for patients with RA. In the case of PsA, it was assessed through modified DAS28 [23], and by Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in AS patients [24]. The explanatory variable was the BMI measured in kg/m$^2$.

Potential confounding factors included socio-demographic factors (such as age, sex, and education level), disease-specific variables (rheumatoid factor (RF), anti-citrullinated peptide antibodies (ACPA), positivity for HLA-B27, erythrocyte sedimentation rate (ESR, mm/h) by Westergren method, C-reactive protein (CRP, mg/L)), DAS28-ESR, modified DAS for PsA, Health Assessment Questionnaire (HAQ, from 0 to 3), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) from 0 to 10 and Bath AS Functional Index (BASFI, from 0 to 10), duration of disease, and administered therapies. The variables of physical activity and smoking are collected through an interview with the patient. Physical activity was classified into three categories: mild, moderate, and high physical activity depending on the hours of exercise per week. Height was measured in the patients at the beginning of the study (visit 0). Data on medication are collected by reviewing the medical history (see supplementary material of [18]).

2.4. Statistical Analysis

A baseline descriptive analysis was performed. Numerical variables with a normal distribution were expressed as mean and standard deviation (SD). Non-normally distributed variables were shown as the median and interquartile range (IQR, P$_{25}$–P$_{75}$). The absolute and relative frequencies of the qualitative variables were also calculated.

Analyses of the main demographic and clinical variables stratified by the type of disease were done. Furthermore, a stratified analysis was performed through linear regression for each group according to activity indices and BMI (kg/m$^2$). Moreover, socio-demographic characteristics and clinical features were analyzed.

To study the relationship between disease activity and BMI (kg/m$^2$), three explanatory models of linear regression were constructed, one for each disease, calculating the beta ($\beta$) coefficient, with 95% confident interval (CI) and adjusting for potential confounding factors.

Data management and statistical analysis were centralized at the Research Unit of the Spanish Rheumatology Society. All analyses were performed using Stata 13.1 copyright 1985–2013 StataCorp LP (Lakeway Drive College Station, Texas, USA).
3. Results

3.1. General Characteristics of the Patients

The total number of patients included in the study was 2234 (775 RA, 738 AS, 721 PsA). Socio-demographic and clinical characteristics of the patients included have been described in previous studies [18] (Table 1), with an increased prevalence of women in the RA group (74.9%) and a greater percentage of men in AS group (72.9%), while sex distribution was almost similar in PsA patients. The average age in patients with RA was higher (57.1 years) than in the other two groups. By contrast, the average BMI and the frequency of obesity were higher in patients with PsA. Furthermore, diabetes was more frequent in PsA patients. The percentage of active smokers was higher in the AS group (34.4%). Remarkably, the majority of CIRD patients included in the study had low disease activity at the time of inclusion in the registry because patients were followed up in outpatient clinics of Rheumatology, mostly under tight control conditions of management of the disease. In keeping with that, the percentage of patients receiving biologic therapy ranged between 41.4% in RA up to 47.2% in AS (Table 1).

Table 1. Main demographic, lifestyle, and clinical characteristics of the patients included in the study.

| Variables                      | Rheumatoid Arthritis (n = 775) | Ankylosing Spondylitis (n = 738) | Psoriatic Arthritis (n = 721) | p    |
|--------------------------------|---------------------------------|----------------------------------|------------------------------|------|
| Age at inclusion, years, mean (SD) | 57.1 (12.3)                     | 48.1 (11.7)                      | 51.8 (12.0)                  | <0.001|
| Age at the beginning of disease, years, mean (SD) | 45.8 (13.4)                     | 29.7 (11.8)                      | 39.5 (13.3)                  | <0.001|
| Female sex, n (%)              | 581 (75.0)                      | 200 (27.1)                       | 327 (45.4)                   | <0.001|
| BMI, kg/m², mean (SD)          | 26.9 (4.8)                      | 27.4 (4.4)                       | 28.2 (4.7)                   | 0.005 |
| Physical activity, years, mean (SD) | 462 (66.1)                     | 453 (69.7)                       | 409 (62.9)                   | 0.035 |
| Smoking, current (%)           | 172 (24.4)                      | 224 (34.1)                       | 136 (20.6)                   | <0.001|
| Past                           | 188 (26.7)                      | 212 (32.3)                       | 216 (32.7)                   | <0.001|
| Ethnicity, Hispanic (%)        | 679 (96.6)                      | 643 (97.9)                       | 654 (99.2)                   | <0.001|
| Educational level              |                                |                                  |                             |      |
| Basic                          | 59 (8.5)                        | 25 (3.8)                         | 32 (4.9)                     | <0.001|
| Primary                        | 367 (52.6)                      | 257 (39.4)                       | 269 (41.2)                   | <0.001|
| Secondary                      | 171 (24.5)                      | 199 (30.5)                       | 189 (28.9)                   | <0.001|
| University                     | 101 (14.5)                      | 172 (26.3)                       | 163 (25.0)                   | <0.001|
| Obesity (BMI ≥ 30), n (%)      | 180 (23.2)                      | 186 (25.2)                       | 209 (29.1)                   | <0.001|
| Disease duration, years, mean (SD) | 8.0 (3.0–14.0)                 | 15.0 (8.0–26.0)                  | 9.0 (4.0–16.0)               | <0.001|
| DAS28-ESR, mean (SD)           | 3.2 (1.2)                       | -                                | 3.0 (1.3)                    | 0.005 |
| BASDAI (0–10), median (P_{25–75}) | -                               | 3.5 (1.7–5.3)                   | -                            | -    |
| HAQ (1–3), median (P_{25–75})  | 0.5 (0.1–1.1)                   | -                                | 0.4 (0.0–0.9)                | <0.001|
| BASFI (0–10), median (P_{25–75}) | -                              | 3.1 (1.3–5.2)                   | -                            | -    |
| ESR, mm/1st h, median (P_{25–75}) | 17.0 (9.0–29.0)                | 10.0 (6.0–21.0)                  | 12.0 (6.0–21.0)              | <0.001|
| CRP, mg/L, median (P_{25–75})  | 3.1 (1.2–8.0)                   | 3.6 (1.6–8.9)                    | 2.9 (1.4–6.1)                | 0.001 |
| ACPA positive (%)              | 420 (59.6)                      | -                                | -                            | -    |
| RF positive (%)                | 541 (76.7)                      | -                                | -                            | -    |
| HLA-B27 positive (%)           | -                               | 498 (75.8)                       | -                            | -    |
| Onicopathy, n (%)              | -                               | 254 (38.5)                       | -                            | -    |
| PASI, median (P_{25–75})       | 0.6 (0.0–2.1)                   | -                                | -                            | -    |
| Enthesitis, median (P_{25–75}) | 0.0 (0.0–1.0)                   | -                                | -                            | -    |
3.2. Association between Body Mass Index and Disease Activity

The effect of BMI on disease activity, estimated as β-coefficient by multivariate linear regression, is shown in Table 2. We found a positive association between BMI and disease activity in patients with RA (β-coefficient: 0.029; 95% CI: 0.01–0.05; p = 0.007) and in those with PsA (β-coefficient: 0.036; 95% CI: 0.015–0.058; p = 0.001). By contrast, there was no significant association between BMI and disease activity in patients with AS (β-coefficient: 0.001; 95% CI: −0.026–0.03; p = 0.926). When categorizing BMI variable as normal weight (BMI < 25), overweight (BMI: 25–30), and obesity (BMI > 30), similar significance was maintained in patients with RA (B-coeff: 0.32; 95% CI:0.067–0.571; p = 0.013), while in PsA, the significance remained only at limited values (B-coeff: 0.27; 95% CI:-0.0026–0.537; p = 0.05), probably due to the reduction in the number of patients in each group, maintaining non-significant values in patients with AS (B-coeff: 0.073; p = 0.662).

In patients with RA, female sex (β-coefficient: 0.546; 95% CI: 0.316–0.775; p < 0.001) and rheumatoid factor status (seropositivity for RF) (β-coefficient: 0.328; 95% CI: 0.106–0.549; p = 0.004) also showed a positive association with disease activity, while physical activity revealed a negative association with disease activity (β-coefficient: −0.280; 95% CI: −0.479–(−0.081); p = 0.006) (Table 2).

Besides BMI, female sex (β-coefficient: 0.720; 95% CI: 0.524–0.916; p < 0.001), Psoriasis Area Severity Index (PASI) (β-coefficient: 0.038; 95% CI: 0.012–0.066; p = 0.005), and enthesitis (β-coefficient: 0.256; 95% CI: 0.199–0.313; p < 0.001) were also positively associated with disease activity in PsA (Table 2).

As observed in RA and PsA, female sex was also associated with disease activity in patients with AS (β-coefficient: 0.565; 95% CI: 0.299–0.832; p < 0.001) (Table 2).
### Table 2. Association between disease activity and epidemiologic and clinical features in patients with CIRD from the CARMA cohort. Multivariate analysis.

| Variables                          | Rheumatoid Arthritis ($n = 775$) | Ankylosing Spondylitis ($n = 738$) | Psoriatic Arthritis ($n = 721$) |
|------------------------------------|----------------------------------|-----------------------------------|----------------------------------|
|                                    | $\beta$ | 95% CI | $p$-Value | $\beta$ | 95% CI | $p$-Value | $\beta$ | 95% CI | $p$-Value |
| BMI (kg/m$^2$)                     | 0.029   | (0.01, 0.05) | 0.007   | 0.001   | (−0.03, 0.03) | 0.926   | 0.036   | (0.015, 0.058) | 0.001 |
| Age at inclusion                   | −0.003  | (−0.01, 0.004) | 0.312   | −0.005  | (−0.02, 0.005) | 0.348   | −0.003  | (−0.011, 0.004) | 0.325 |
| Sex (reference, male)              | 0.545   | (0.316, 0.775) | <0.001  | 0.565   | (0.299, 0.832) | <0.001  | 0.720   | (0.524, 0.916) | <0.001 |
| Ethnicity (reference, Caucasian)   |         |        |          |         |        |          |         |        |          |
| Hispanic                           | −0.234  | (−0.810, 0.343) | 0.426   | 0.422   | (−0.788, 1.633) | 0.493   | 1.077   | (−0.529, 2.684) | 0.188 |
| Other                              | −0.789  | (−1.986, 0.406) | 0.195   | 0.119   | (−1.095, 1.334) | 0.847   | −1.370  | (−2.977, 0.237) | 0.095 |
| Physical activity (reference, no)  | −0.280  | (−0.479, −0.081) | 0.006   | 0.0009  | (−0.260, 0.262) | 0.994   | −0.100  | (−0.296, 0.095) | 0.313 |
| Educational level                  |         |        |          |         |        |          |         |        |          |
| Primary                            | −0.136  | (−0.481, 0.201) | 0.437   | 0.374   | (−0.254, 1.004) | 0.242   | −0.358  | (−0.80, 0.083) | 0.112 |
| Secondary                          | −0.350  | (−0.732, 0.035) | 0.075   | 0.332   | (−0.311, 0.975) | 0.311   | −0.538  | (−0.999, −0.076) | 0.022 |
| University                         | −0.137  | (−0.551, 0.275) | 0.513   | 0.321   | (−0.341, 0.984) | 0.341   | −0.540  | (−1.009, −0.075) | 0.024 |
| Smoking (ref., current smokers)    |         |        |          |         |        |          |         |        |          |
| Past smokers (>1 year)             | 0.102   | (−0.166, 0.370) | 0.455   | −0.043  | (−0.330, 0.242) | 0.765   | 0.081   | (−0.188, 0.352) | 0.552 |
| Never smokers                      | 0.081   | (−0.157, 0.319) | 0.504   | 0.010   | (−0.279, 0.300) | 0.942   | −0.049  | (−0.299, 0.200) | 0.696 |
| Rheumatoid factor + (reference, no)| 0.328   | (0.106, 0.549) | 0.004   | NA      | NA      | NA      | NA      | NA      | NA      |
| HLA-B27 + (reference, no)          | NA      | NA      | NA      | −0.099  | (−0.376, 0.178) | 0.484   | NA      | NA      | NA      |
| BASFI                              | NA      | 0.656   | (0.608, 0.706) | <0.001  | NA      | NA      | 0.038   | (0.012, 0.066) | 0.005 |
| PASI                               | NA      | NA      | NA      | 0.256   | (0.199, 0.313) | <0.001  | NA      | NA      | NA      |
| Enthesitis                         | NA      | NA      | NA      | 0.155   | (−0.034, 0.346) | 0.109   | NA      | NA      | NA      |
| Onicopathy (reference, no)         | NA      | NA      | NA      | −0.059  | (−0.341, 0.223) | 0.680   | 0.028   | (−0.023, 0.286) | 0.829 |
| Conventional DMARDs (ref., no)     | −0.059  | (−0.341, 0.223) | 0.680   | 0.028   | (−0.023, 0.286) | 0.829   | 0.193   | (−0.029, 0.415) | 0.089 |
| Biologic DMARDs (reference, no)    | 0.095   | (−0.10, 0.29) | 0.338   | −0.431  | (−0.665, −0.198) | <0.001  | −0.353  | (−0.553, −0.154) | 0.001 |
| Glucocorticoids (reference, no)    | 0.187   | (0.001, 0.373) | 0.049   | 0.373   | (−0.054, 0.802) | 0.087   | 0.326   | (0.083, 0.570) | 0.008 |

BASFI: Bath Ankylosing Spondylitis (AS) Functional Index; BMI: body mass index; CARMA: CARDiovascular in RheuMATology; CIRD: chronic inflammatory rheumatic diseases; DMARD(s): disease-modifying anti-rheumatic drugs; HLA-B27: Human leucocyte antigen B27; PASI: Psoriasis Area Severity Index. Data are expressed as β-coefficients (95% CI) and p-values. NA: not applicable.
4. Discussion

The main findings of this study support an association of BMI with disease activity in RA and PsA but not with AS. In addition, specific features of each CIRD were associated with disease activity. It was the case for RF status in patients with RA and PASI and the presence of enthesitis in those with PsA. Central obesity is one of the components of the metabolic syndrome that is frequently observed in patients with CIRD, in particular in those with RA and PsA [25–27].

The reason for the absence of the association of BMI with disease activity in patients with AS from the CARMA project is unknown. With respect to this, AS patients included in the CARMA cohort had low disease activity and almost half of them were undergoing biologic therapy. In this regard, it may be of potential interest to highlight that the anti-TNF monoclonal antibody-IFX was more frequently used in AS (18.3%) than in RA (6.2%) and PsA (10.1%). Given that IFX is a biological agent that is administered adjusted to the weight of the subject, we wondered if this could lead to an optimal response and less disease activity in this group of patients. According to this possibility, Micheroli et al. reported that axial spondyloarthritis obese patients treated with IFX had a better response compared to those treated with other anti-TNF agents not adjusted to corporal weight [16]. Another possible explanation may be that the implication of the metabolic syndrome and, consequently, of the proinflammatory adipokines in AS appears to be less important than that played in the other two CIRDs. On the other hand, our data also supported the potential beneficial effect of regular physical activity and weight loss on the control of the underlying disease in individuals with RA.

Obesity and overweight have an important role in the development of psoriasis and PsA. In a cohort study among 75,395 individuals with psoriasis (43% male, mean age of 52 years, and mean follow-up of 5 years) conducted in the UK, 976 developed PsA (incidence rate of 26.5 per 10,000 person-years) [28]. The PsA incidence rates augmented with increasing BMI. Compared to psoriasis patients with BMI < 25 kg/m², the relative risk for developing PsA was 1.09 (0.93–1.28) for BMI from 25.0 to 29.9, 1.22 (1.02–1.47) for BMI from 30.0 to 34.9, and 1.48 (1.20–1.81) for BMI ≥ 35 [28]. In another study including 89,049 participants from the Nurses’ Health Study II followed over a 14-year period, 146 incident PsA cases were identified during 1,231,693 person-years of follow-up. Among all participants, BMI was associated with an increased risk of incident PsA [29]. There was a graded positive association between weight change from age 18 years, measures of central obesity, and risk of PsA. The analysis among participants developing psoriasis during the follow-up revealed a similar association, indicating an increased risk of PsA associated with obesity among patients with psoriasis [29]. These two studies suggest that obesity is associated with an increased risk of incident PsA and supports the importance of weight control among psoriatic patients who often suffer from metabolic syndrome and obesity. As previously reported by other authors [17,30–33], obese patients from the CARMA cohort were treated more commonly with biologic therapies than normal-weight individuals.

Finally, besides its direct effect on inflammation through increased proinflammatory cytokines secretion, obesity can also influence treatment response by modifying pharmacokinetics of biologic antirheumatic drugs. In fact, population studies have identified high body weight as a risk factor for increased clearance of anti-TNF agents, resulting in shorter half-life and lower serum drug concentrations [34]. By contrast, there is strong clinical evidence that while TNF blockers may be less effective in obese patients, the efficacy of T cell co-stimulation inhibition, B-cells depletion, and IL-6 blocking seems not to be negatively influenced by the amount of body fat [35].

Our study has some strengths. It includes an important national multicenter cohort of patients with RA, AS, and PsA prospectively followed up at the outpatient clinics to detect the incidence of cardiovascular events over 10 years of follow-up, being the first study in our country that tries to establish an association between BMI and inflammatory activity in patients with these three diseases. However, it has also some limitations. Many of the patients included in this study had low disease activity at the time of recruitment.
In fact, our patients were under a tight control strategy and a high number of them were undergoing biologic therapy at recruitment. This management may have had decreased some of the disease activity parameters used, thus interfering in the results. In this regard, obesity is a modifiable factor in our clinical practice that not only plays an important role in cardiovascular risk and morbidity but its control would also imply better management of the inflammatory disease and better efficiency of the treatments, especially biological agents, used in these patients.

In summary, a relationship between BMI and disease activity was observed in patients with CIRD from the CARMA cohort, especially in patients with RA and PsA. This finding could not be demonstrated in patients with AS, where the proportion of patients treated with biologic therapy was higher, which could have modified the results obtained.

Adequate control over body weight may improve the outcome of patients with inflammatory joint diseases and, therefore, weight control should be included in the strategy of management of these patients.

Author Contributions: J.A.V.-J., R.L.-G., M.A.M.-M., S.C., and M.A.G.-G. performed to the design of the study; M.A.M.-M., J.T.S.-C., and F.S.-A. conducted the data analysis; J.A.V.-J., R.L.-G., M.A.M.-M., S.C., J.T.S.-C., J.L., and M.A.G.-G. contributed to the data interpretation and manuscript drafting. Rest of the authors contributed to the collection of the data. C.G.-J., J.L., and F.S.-A. helped interpret the data and strengthen the manuscript. M.A.G.-G. helped design and developed the CARMA project, assisted in data interpretation, and was responsible for the final draft of the manuscript. All the authors read, discussed, and approved the final manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This project has been supported by an unrestricted grant from Abbvie, Spain. Nonetheless, the design, analysis, interpretation of results, and preparation of the manuscript have been done independently of Abbvie. Professor González-Gay’s studies have been supported by grants from “Fondo de Investigaciones Sanitarias” PI06/0024, PS09/00748, PI12/00060, PI15/00525, PI18/00043, and RD12/0009/0013 and RD16/0012 (RIER) from “Instituto de Salud Carlos III” (ISCIII) (Spain), co-funded by FEDER funds.

Institutional Review Board Statement: This study was performed following the principles outlined in the Helsinki Declaration, and the study protocol was approved by the Ethics Committee for Clinical Research of Lugo, Galicia, Spain, and then by all participant centers (protocol number: 2009/077).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Acknowledgments: This publication was aided by members of the Research Unit of the SER. The authors thank all the patients who generously participated in this study. Furthermore, the authors acknowledge the approval of the study from all participating centers.

Conflicts of Interest: The authors declare that they have no competing interests regarding this manuscript.

CARMA Project Collaborative Group: Members of the CARdiovascular in rheuMAtology Project Collaborative Group include: José Antonio Pinto-Tasende, Elena Alonso Blanco Morales, J. Carlos Fernández López, Natividad Oreiro Villar, Antonio Atanes Sandoval, Francisco J. Blanco García (Complejo Hospitalario A Coruña, Xubias de Arriba, A Coruña); Cayetano Alegre De Miquel, María J. González Fernández, Ramón Huguet Codina, Beatriz Yoldi, Mercedes Ramentol (Instituto Dexeus, Barcelona); Sara Marsal Barril, María Lopez Lasanta, Susana Antón, Estefanía Quesada (Hospital Universitari Vall d’Hebron, Barcelona); Martina Steiner, Santiago Muñoz, Tatiana Cobo (Hospital Infanta Sofía, Madrid); María del Puerto Moreno Gil, Fernando Gamero, José García Torrán, (Hospital S. Pedro de Alcántara, Cáceres); Antonio Juan Mas, Pilar Espino, Inmaculada Ros, Mónica Ibáñez, Claudia Murillo, Catalina Melia Mesquida, Ana Paula Cacheda (Hospital Son Llatzer, Palma de Mallorca); Jesús Tornero Molina (Hospital Univ. de Guadalajara); Raïmon Samartí, Horacio Berman, Sonia Cabrera, Virginia Ruiz, Raül A. Castellanos Moreira, Sebastián C. Rodríguez García (Hospital Clinic i Provincial, Barcelona); Benjamín Fernández Gutiérrez, Luis Rodríguez Rodríguez, Lydia Abasolo, Oscar Fontseré Patón (Hospital Clínico Univ. San Carlos, Madrid); José M. Pina, Dolores Fábregas Canals (Hospital de Barbastro, Huesca);Montserrat Romero, Joan M. Nolla, (Hospital Univ. de Bellvitge, Barcelona); Miriam García Arias, Mirem Uriarte Ecenarro, Jesús A. García Vadillo,
Castañeda, S.; Nurmohamed, M.T.; Gonzalez-Gay, M.A. Cardiovascular disease in inflammatory rheumatic diseases.

lbrecht, K.; Richter, A.; Callhoff, J.; Huscher, D.; Schett, G.; Strangfeld, A.; Zink, A. Body mass index distribution in rheumatoid arthritis.

World Health Organization Guideline. World Health Organization Website. Published 2019. Available online: https://www.who.int/publications/i/item/2019/4.

References

1. World Health Organization Guideline. World Health Organization Website. Published 2019. Available online: https://www.who.int/publications/i/item/2019/4.

2. Aranceta-Barrina, J.; Bartrina, J.A.; Alberdi-Arostegui, G.; Ramos-Carrera, N.; Lázaro-Masedo, S. Prevalence of General Obesity and Abdominal Obesity in the Spanish Adult Population (Aged 25–64 Years) 2014–2015: The ENPE Study. Revista Española De Cardiología (Engl. Ed.) 2016, 69, 579–587. [CrossRef] [PubMed]

3. Russolillo, A.; Iervolino, S.; Peluso, R.; Lupoli, R.; Di Minno, A.; Pappone, N.; Di Minno, M.N.D. Obesity and psoriatic arthritis: From pathogenesis to clinical outcome and management. Rheumatology 2013, 52, 62–67. [CrossRef] [PubMed]

4. lbrecht, K.; Richter, A.; Callhoff, J.; Huscher, D.; Schett, G.; Strangfeld, A.; Zink, A. Body mass index distribution in rheumatoid arthritis: A collaborative analysis from three large German rheumatoid arthritis databases. Arthritis Res. Ther. 2016, 18, 149. [CrossRef]

5. Castañeda, S.; Nurmohamed, M.T.; Gonzalez-Gay, M.A. Cardiovascular disease in inflammatory rheumatic diseases. Best Pr. Res. Clin. Rheumatol. 2016, 30, 851–869. [CrossRef] [PubMed]

6. Maas, F.; Arends, S.; van der Veer, E.; Wink, F.; Efde, M.; Bootsma, H.; Brouwer, E.; Spoor, A. Obesity is common in axial spondyloarthritis and associated with poor clinical outcome. J. Rheumatol. 2016, 43, 383–387. [CrossRef]

7. Giles, J.T.; Bartlett, S.J.; Anderson, R.; Thompson, R.; Fontaine, K.R.; Bathon, J.M. Association of body fat with C-reactive protein in rheumatoid arthritis. Arthritis Rheum. 2008, 58, 2632–2641. [CrossRef]
8. Di Minno MN, D.; Peluso, R.; Iervolino, S.; Lupoli, R.; Russolillo, A.; Scarpa, R.; Di Minno, G. Obesity and the prediction of minimal disease activity: A prospective study in Psoriatic Arthritis. *Arthritis Care Res.* 2013, 65, 141–147. [CrossRef]

9. Dreesen, E.; Gilis, A.; Vermeire, S. Pharmacokinetic Modeling and Simulation of Biologicals in Inflammatory Bowel Disease: The Dawning of a New Era for Personalized Treatment. *Curr. Drug Targets* 2018, 19, 757–776. [CrossRef]

10. Eder, L.; Thavaneswaran, A.; Chandran, V.; Cook, R.J.; Gladman, D.D. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. *Ann. Rheum. Dis.* 2015, 74, 813–817. [CrossRef]

11. Ordás, I.; Mould, D.R.; Feagan, B.G.; Sandborn, W.J. Anti-TNF monoclonal antibodies in obesity and treatment of inflammatory bowel disease: Pharmacokinetics-based dosing paradigms. *Clin. Pharmacol. Ther.* 2012, 91, 635–646. [CrossRef]

12. Liu, Y.; Hazlewood, G.S.; Kaplan, G.G.; Eksteen, B.; Barnabe, C. Impact of Obesity on Remission and Disease Activity in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. *Arthritis Care Res.* 2017, 69, 157–165. [CrossRef] [PubMed]

13. Bakirci, S.; Dabagie, J.; Eder, L.; McGonagle, D.; Aydin, S.Z. The role of obesity on inflammation and damage in spondyloarthritis: A systematic literature review on body mass index and imaging. *Clin. Exp. Rheumatol.* 2019, 38, 144–1448. [PubMed]

14. Vargas, R.R.; van den Berg, R.; van Lunteren, M.; Ez-Zaitouni, Z.; Bakker, P.A.C.; Dagfinrud, H.; Ramonda, R.; Landewé, R.; Molenar, E.; van Gaalen, F.A.; et al. Does body mass index (BMI) influence the Ankylosing Spondylitis Disease Activity Score in axial spondyloarthritis? Data from the SPACE cohort. *RMD Open* 2016, 2, e000283. [CrossRef] [PubMed]

15. Ottaviani, S.; Allonore, Y.; Tubach, F.; Forien, M.; Gardette, A.; Pasquet, B.; Palazzo, E.; Meunier, M.; Hayem, G.; Job-Deslandre, C.; et al. Body mass index influences the response to infliximab in ankylosing spondylitis. *Arthritis Res. Ther.* 2012, 14, R115. [CrossRef] [PubMed]

16. Micheroli, R.; on behalf of the rheumatologists of the Swiss Clinical Quality Management Program; Hebeisen, M.; Wildi, L.M.; Exer, P.; Tamborrini, G.; Bernhard, J.; Möller, B.; Zufferey, P.; Nissen, M.J.; et al. Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis. *Arthritis Res. Ther.* 2017, 19, 164. [CrossRef]

17. Gremske, E.; Bernardi, S.; Bonazza, S.; Nowik, M.; Peluso, G.; Massara, A.; Tolusso, B.; Messuti, L.; Miceli, M.C.; Zoli, A.; et al. Body weight, gender and response to TNF-α blockers in axial spondyloarthritis. *Rheumatology* 2014, 53, 875–881. [CrossRef]

18. Castañeda, S.; Martínez, M.A.; González-Juanatey, C.; Llorca, J.; García-Yébenes, M.J.; Pérez-Vicente, S.; Sánchez-Costa, J.T.; Díaz-González, F.; González-Gay, M.A.; CARMA Project Collaborative Group. CARMA Project Collaborative Group. Cardiovascular morbidity and associated risk factors in Spanish patients with chronic inflammatory rheumatic diseases attending rheumatology clinics: Baseline data of the CARMA Project. *Semin. Arthritis Rheum.* 2015, 4, 618–626. [CrossRef]

19. Arnett, F.C.; Edworthy, S.M.; Bloch, D.A.; McShane, D.J.; Fries, J.F.; Cooper, N.S.; Healey, L.A.; Kaplan, S.R.; Liang, M.H.; Luthra, H.S.; et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum.* 1988, 31, 315–324. [CrossRef] [PubMed]

20. van der Linden, S.; Valkenburg, H.A.; Cats, A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. *Arthritis Rheum.* 1984, 27, 361–368. [CrossRef]

21. Moll, J.M.; Wright, V. Psoriatic arthritis. *Semin. Arthritis Rheum.* 1973, 3, 55–78. [CrossRef]

22. van der Heijde, D.M.; van’t Hof, M.; van Riel, P.L.; van de Putte, L.B. Development of a disease activity score based on judgment in clinical practice by rheumatologists. *J. Rheumatol.* 1993, 20, 579–581.

23. Ujfalussy, I.; Kőö, É. Measurement of disease activity in psoriatic arthritis. *Zeitschrift für Rheumatologie* 2003, 62, 60–65. [CrossRef] [PubMed]

24. Garrett, S.; Jenkinson, T.; Kennedy, L.G.; Whitelock, H.; Gaisford, P.; Calin, A. A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. *J. Rheumatol.* 1994, 21, 2286–2291. [PubMed]

25. Kerekes, G.; Nurmohamed, M.T.; González-Gay, M.A.; Seres, I.; Parag, G.; Kardos, Z.; Baráth, Z.; Tamás, L.; Soltész, P.; Szekanecz, Z. Rheumatoid arthritis and metabolic syndrome. *Nat. Rev. Rheumatol.* 2014, 10, 691–696. [CrossRef] [PubMed]

26. Ferraz-Amaro, I.; González-Juanatey, C.; López-Mejias, R.; Riancho-Zarrabeitia, L.; González-Gay, M.A. Metabolic Syndrome in Rheumatoid Arthritis. *Nat. Rev. Rheumatol.* 2014, 10, 635–646. [CrossRef] [PubMed]

27. Molenaar, E.; van Gaalen, F.A.; et al. Does body mass index (BMI) influence the Ankylosing Spondylitis Disease Activity Score in axial spondyloarthritis? *Arthritis Res. Ther.* 2013, 15, 310928. [CrossRef]

28. Mok, C.C.; Ko, G.T.C.; Ho, L.Y.; Yu, K.L.; Chan, P.T.; To, C.H. Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. *Arthritis Rheum.* 2011, 63, 195–202. [CrossRef]

29. Love, T.J.; Zhu, Y.; Zhang, Y.; Wall-Burns, L.; Ogdie, A.; Gelfand, J.M.; Choi, H.K. Obesity and the risk of psoriatic arthritis: A population-based study. *Ann. Rheum. Dis.* 2012, 71, 1273–1277. [CrossRef]

30. Li, W.; Han, J.; Qureshi, A.A. Obesity and risk of incident psoriatic arthritis in US women. *Ann. Rheum. Dis.* 2012, 71, 1267–1272. [CrossRef]

31. Di Minno MN, D.; Peluso, R.; Iervolino, S.; Russolillo, A.; Lupoli, R.; Scarpa, R.; CaRRDs Study Group. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor alfa blockers. *Ann. Rheum. Dis.* 2014, 73, 1157–1162. [CrossRef]

32. Singh, S.; Facciorusso, A.; Singh, A.G.; Vande Casteele, N.; Zarrinpar, A.; Prokop, L.J.; Grunvald, E.L.; Curtis, J.R.; Sandborn, W.J. Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. *PLoS ONE* 2018, 13, e0195123. [CrossRef] [PubMed]

33. Schulman, E.; Bartlett, S.J.; Schieir, O.; Andersen, K.M.; Boire, G.; Pope, J.E.; Hitchon, C.; Jamal, S.; Thorne, C.; Tin, D.; et al. Overweight, Obesity, and the Likelihood of Achieving Sustained Remission in Early Rheumatoid Arthritis: Results from a Multicenter Prospective Cohort Study. *Arthritis Rheumatol.* 2018, 70, 1185–1191. [CrossRef] [PubMed]
33. Sandberg, M.E.C.; Bengtsson, C.; Källberg, H.; Wesley, A.; Klareskog, L.; Alfredsson, L.; Saevarsdottir, S. Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis. *Ann. Rheum. Dis.* **2014**, *73*, 2029–2033. [CrossRef] [PubMed]

34. Passot, C.; Mulleman, D.; Bejan-Angoulvant, T.; Aubourg, A.; Willot, S.; LeComte, T.; Picon, L.; Goupille, P.; Paintaud, G.; Ternant, D. The underlying inflammatory chronic disease influences infliximab pharmacokinetics. *mAbs* **2016**, *8*, 1407–1416. [CrossRef]

35. Moroni, L.; Farina, N.; Dagna, L. Obesity and its role in the management of rheumatoid and psoriatic arthritis. *Clin. Rheumatol.* **2020**, *39*, 1039–1047. [CrossRef] [PubMed]